- Conditions
- Gastroesophageal Reflux Disease, Hiatal Hernia
- Interventions
- Laparoscopic Fundoplication, LINX Antireflux
- Procedure · Device
- Lead sponsor
- The Heartburn Foundation
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,941 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Heber Springs, Arkansas + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1753–1776
of 9,530
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- ADC3680, Placebo, montelukast
- Drug
- Lead sponsor
- Pulmagen Therapeutics
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Huntington Beach, California • Riverside, California + 32 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- ALN-6400, Placebo
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
- Conditions
- Coronary Arteriosclerosis
- Interventions
- Rosuvastatin calcium
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 21 more
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Sexual Dysfunction
- Interventions
- 36.25 Gy IMRT, 51.6 Gy IMRT
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 25 more
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 40,805 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 188
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
- Conditions
- Chronic Low-back Pain
- Interventions
- LY3016859, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Irvine, California + 28 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 634 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 103
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 76 more
- Conditions
- Cerebrovascular Accident
- Interventions
- Balance Task Training with therapist guarding support, Balance task training with robotic guarding support, Challneged balance task training with robotic guarding support
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Severe Combined Immunodeficiency (SCID), Leaky SCID, Omenn Syndrome, Reticular Dysgenesis, ADA SCID, XSCID
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 7 more
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
- Interventions
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
- Procedure · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 1,377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 168
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
- Conditions
- Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
- Interventions
- liposomal T4N5 lotion, placebo, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Coronary Artery Disease
- Interventions
- pexelizumab in conjunction with CABG
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 182
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 129 more
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- ERAS-601, Cetuximab, Pembrolizumab
- Drug
- Lead sponsor
- Erasca, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
- Conditions
- BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
- Interventions
- clindamycin phosphate vaginal cream 2%, placebo
- Drug · Other
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 604 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Certolizumab pegol
- Other · Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- teriparatide, aldrenodate, raloxifene
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 7 more
- Conditions
- Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease
- Interventions
- GDC-6988
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Palo Alto, California • Kansas City, Kansas + 3 more
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- cyclosporine, etoposide, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 54 more
- Conditions
- HIV Infections
- Interventions
- IMVAMUNE (MVA-BN)
- Biological
- Lead sponsor
- Bavarian Nordic
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 581 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Burbank, California + 29 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- LY2951742, Placebo- oral, Placebo - SC, Celecoxib
- Drug · Other
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 38
- States / cities
- Birmingham, Alabama • Anaheim, California • San Diego, California + 31 more
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- NNC0194 0499 50 mg/mL, Placebo (NNC0194-0499), Semaglutide 3 mg/mL, Semaglutide placebo, NNC0174 0833 10 mg/mL, NNC0174 0833 placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 698 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 70
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 59 more
- Conditions
- Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Glycogenesis 2 Acid Maltase Deficiency
- Interventions
- alglucosidase alfa
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Stanford, California • Washington D.C., District of Columbia + 6 more